Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor.
In a murine relapsing experimental allergic encephalomyelitis (EAE) model, gene therapy to block TNF was investigated with the use of a retroviral dimeric p75 TNF receptor (dTNFR) construct. To effectively produce these TNF inhibitors in vivo, a conditionally immortalized syngeneic fibroblast line w...
Main Authors: | Croxford, J, Triantaphyllopoulos, K, Neve, R, Feldmann, M, Chernajovsky, Y, Baker, D |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2000
|
Similar Items
-
Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system.
by: Croxford, J, et al.
Published: (1998) -
Different therapeutic outcomes in experimental allergic encephalomyelitis dependent upon the mode of delivery of IL-10: a comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system.
by: Croxford, J, et al.
Published: (2001) -
The murine p75 TNF receptor promoter region: DNA sequence and characterization of a cis-acting silencer.
by: Kissonerghis, M, et al.
Published: (1999) -
Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins.
by: Baker, D, et al.
Published: (1994) -
Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis.
by: Croxford, J, et al.
Published: (1998)